5-iodo-2-((trimethylsilyl)oxy)pyrimidine | 88350-65-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-iodo-2-((trimethylsilyl)oxy)pyrimidine
• 英文别名: 5-Iodo-2-trimethylsilyloxypyrimidine；(5-iodopyrimidin-2-yl)oxy-trimethylsilane
• CAS: 88350-65-6
• 化学式: C₇H₁₁IN₂OSi
• 分子量: 294.167
• InChiKey: WCLPLNIOLJYSJN-UHFFFAOYSA-N

物化性质

• 沸点：
  280.2±32.0 °C(Predicted)
• 密度：
  1.542±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.29
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Alpha,4-二氯茴香醚 、 5-iodo-2-((trimethylsilyl)oxy)pyrimidine 反应 0.25h， 以60%的产率得到1-[(4-氯苯氧基)甲基]-5-碘嘧啶-2-酮
  参考文献：
  名称：

  Benneche, Tore; Undheim, Kjell, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1983, vol. 37, # 4, p. 345 - 350

  摘要：

  DOI：
• 作为产物：
  描述：

  5-碘-2-嘧啶酮 生成 5-iodo-2-((trimethylsilyl)oxy)pyrimidine
  参考文献：
  名称：

  Organic Process Research and Development. 1999, 3, 135-138

  摘要：

  DOI：

文献信息

• [EN] IDOXURIDINE AND ITS ANALOGS AS NEUROPROTECTANS FOR THE TREATMENT OF PARKINSONISM<br/>[FR] IDOXURIDINE ET SES ANALOGUES UTILISÉS COMME NEUROPROTECTEURS POUR LE TRAITEMENT DU PARKINSONISME
  申请人：SVENNINGSSON PER

  公开号：WO2018143893A1

  公开（公告）日：2018-08-09

  The invention relates to compounds that are useful in the treatment of parkinsonism, such as parkinsonism in connection with Parkinson's disease (PD); dementia with Lewy bodies (DLB); multiple system atrophy (MSA); corticobasal degeneration (CBD); or progressive supranuclear palsy (PSP). The said compounds include in particular idoxuridineand analogs thereofas well as their metabolic precursors, such as ropidoxuridine.The invention further relates to method for identifying compounds useful for the treatment of parkinsonism, said methods comprising detecting the capability of compound to increase the amount of GPR37 in cell membranes.The invention further relates to methods for the chemical synthesis of ropidoxuridine.

  本发明涉及一种在帕金森病（PD）相关的帕金森综合征，如帕金森病（PD）；具有Lewy小体的痴呆（DLB）；多系统萎缩（MSA）；皮质基底节变性（CBD）；或进行性核上性麻痹（PSP）等治疗中有用的化合物。所述化合物包括特别是碘沙宝嘌呤及其类似物以及它们的代谢前体，如罗匹沙宝嘌呤。本发明还涉及一种用于鉴定治疗帕金森综合征的有用化合物的方法，该方法包括检测化合物增加细胞膜中GPR37数量的能力。本发明还涉及罗匹沙宝嘌呤的化学合成方法。
• Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribosides
  作者：Simon M. N. Efange、Elaine M. Alessi、H. C. Shih、Yung Chi Cheng、Thomas J. Bardos

  DOI：10.1021/jm00145a010

  日期：1985.7

  and 2b, respectively, with 3,5-bis-O-(p-chlorobenzoyl)-2-deoxy-alpha-D-ribofuranosyl chloride (8) in 1,2-dichloroethane, in the presence of SnCl4, followed by separation of the anomeric blocked nucleosides via column chromatography and subsequent deprotection with methanolic ammonia. Both BrPdR and IPdR exhibited significant antiherpes activities against various strains of HSV-1 and HSV-2, the latter

  1-（2-脱氧-β-D-呋喃核糖基）-5-溴-2-嘧啶酮（BrPdR）和1-（2-脱氧-β-D-核糖基呋喃糖基）-5-碘-2-嘧啶酮（IPdR）具有通过分别将适当的甲硅烷基化碱2a和2b与1,3-二氯乙烷中的3,5-双-O-（对氯苯甲酰基）-2-脱氧-α-D-呋喃呋喃糖基氯（8）缩合来合成，在SnCl 4存在下，随后通过柱色谱分离异头保护的核苷，随后用甲醇氨脱保护。BrPdR和IPdR均对各种HSV-1和HSV-2菌株均表现出显着的抗疱疹活性，后一种化合物（IPdR）表现出更高的活性以及与病毒特异性胸苷激酶的更强结合。
• Novel 5-substituted 2-pyrimidinone nucleosides and methods of use
  申请人：The Research Foundation of State University of New York

  公开号：US04782142A1

  公开（公告）日：1988-11-01

  Compounds for inhibiting the replication of DNA viruses which induce the formation of thymidine kinase enzyme of the formula: ##STR1## wherein R.sub.1 is a radical selected from the group consisting of chloro, iodo, hydroxy, alkoxyalkyl, hydroxyalkyl, methylamino, formyl, nitro, and unsubstituted hydrocarbon groups of 2 to about 3 carbon atoms or halosubstituted hydrocarbon groups of 1 to about 3 carbon atoms; R.sub.2 is hydrogen or hydroxy; and R.sub.3 is hydroxy, --OP(O)(OH).sub.2, amino, or --OCOR.sub.4 where R.sub.4 is alkyl or alkoxyalkyl of 2 to about 18 carbon atoms.

  抑制诱导胸腺嘧啶激酶酶形成的DNA病毒复制化合物的公式为：##STR1##其中R.sub.1是选择自氯，碘，羟基，烷氧基烷基，羟基烷基，甲基氨基，甲酰基，硝基和未取代的2至约3个碳原子的碳氢基团或1至约3个碳原子的卤代碳氢基团的基团；R.sub.2是氢或羟基；R.sub.3是羟基，--OP（O）（OH）.sub.2，氨基或--OCOR.sub.4，其中R.sub.4是2至约18个碳原子的烷基或烷氧基烷基。
• 5-ioso-2-pyrimidinone nucleoside
  申请人：The Research Foundation of State University of New York

  公开号：US04895937A1

  公开（公告）日：1990-01-23

  The nuceoside 1-(2-Deoxy-.beta.-D-ribofuranosyl)-5-(iodo)-2-pyrimidinone possesses a high level of antiviral activity and a low level of toxicity to the host cell making it an especially effective therapeutic agent for HSV-2.

  核苷1-（2-脱氧-β-D-核糖呋喃基）-5-（碘）-2-嘧啶酮具有高水平的抗病毒活性和对宿主细胞的低毒性，使其成为HSV-2特别有效的治疗剂。
• BENNECHE, T.;UNDHEIM, K., ACTA CHEM. SCAND., 1983, 37, N 4, 345-349
  作者：BENNECHE, T.、UNDHEIM, K.

  DOI：——

  日期：——